Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico

TTFactor @ Laboratori dal Basso

Jacopo Franchini, Business Development Manager TTFactor S.r.l.

Laboratori dal Basso “Geni Mutanti” Campus Ecotkne - Lecce

7 November 2014

“Dalla Ricerca al prodotto, dal prodotto al Mercato”


1.   Doing Technology Transfer for 3 research center in Milano -‐  IEO -‐ IFOM -‐ Monzino

2.   Why should industry and academia collaborate? 3.   TTFactor in this context : A Tech Transfer Company 4.   Career development session

INDEX


•  European InsLtute of Oncology (IEO)

•  FIRC InsLtute of Molecular Oncology (IFOM)

•  Centro Cardiologico Monzino

1.   Doing Technology Transfer for..


•  Founded in 1994, as a Comprehensive Cancer Center •  Private company owned by the major Italian Banks and Insurances,

part of the Na>onal Health System (IRCSS)

The Main Actors (1) • The European Ins>tute of Oncology

•  Clinical Cancer Center •  Research Laboratories


•  Founded in 1999, as a Reaseach InsLtute focused on Basic Cancer Research

•  Founda>on, owned by FIRC, the largest cancer-‐research Italian charity

The Main Actors (2) • The FIRC Ins>tute of Molecular Oncology


The Main Actors (3) • The Campus IFOM-‐IEO

Together, Ifom and Ieo, Founded the campus to expand, integrate their research acBviBes and to exploit the resultant synergies:

Ø  Virtual ins>tu>on; Common Facili>es (imaging, proteomic, genomic etc.) scien>fic governance entrusted to the Scien>fic Directors of IEO and IFOM; common policies.


•  Part of IEO’s group Founded in 1981 and IRCCS since 1992 •  Private Hospital owned by IEO and part of the Na>onal Health System

(IRCSS)

•  THE ONLY RESEARCH HOSPITAL IN EUROPE EXCLUSIVELY DEVOTED TO THE TREATMENT OF CARDIOVASCULAR

DISEASES

•  1ST RANKED FOR CARDIO-‐VASCULAR SURGERY RESULTS BY THE ITALIAN MINISTRY OF HEALTH

•  MAJOR TRANSLATIONAL RESEARCH PROGRAMS AT CCM:

1.   BIOLOGY AND BIOCHEMISTRY OF ATHEROTHROMBOSIS

2.   VASCULAR BIOLOGY AND REGENERATIVE MEDICINE

3.   IMMUNOLOGY AND FUNCTIONAL GENOMICS OF THE PLAQUE

4.   CARDIOVASCULAR TISSUE ENGINEERING

…. And Centro Cardiologico Monzino

TTFactor @ Bocconi

The IEO Clinical Center 1400 Clinics

The IFOM-‐IEO Campus 450 Researchers 40 Research Groups 130 PhD Students (SEMM) 150 Post-‐Docs 50 Scien>sts/Technicians (Scien>fic Groups) 80 Scien>sts/Technicians (Cogentech)

Centro Cardiologico Monzino 644 Clinics 60 Research

The Main actors (4): People involved

TTFactor @ Bocconi

The IFOM-‐IEO Campus To adopt an approach driven by scienLfic curiosity and strongly based on fundamental biology

The IEO Clinical Center To provide the academic home and integrated resources to advance clinical science

•  To favor and accelerate transfer of knowledge for cancer preven>on and treatment

•  To build on the value of scien>fic research with a strictly non-‐profit research

Vision


Main drivers: •  To increase R&D produc0vity; •  To share the development costs/risks with a commercial

partner; •  To advance clinical science for pa3ent benefit; •  To find new medical solu3ons based on scien3fic results;

2) Why should industry and academia collaborate?


Discovery

Phase I

FDA Review/ Approval

Additional post-marketing tests

Phase III

Phase II

Preclinical Tests

Target Discovery Target Validation (2-10 Years)

Test in lab and animal models

20-80 patients; safety and Max Tollerated Dose (MTD)

100-300 patients: efficacy and side effects

1000-1500 patients: adverse events; overall survival

MARKET LAUNCH

The Long journey from R&D to the Market


Stage

Discovery

Pre-‐clinical

Clinical

Fda/ Emea Marke>ng Approval

Time

2-‐10 yrs

2-‐3 yrs

4-‐6 yrs

1-‐2 yrs

Compound Success Rate

10,000

250

10

1

Total Time: 12 years Total investment: 800-‐900 Mln Euro 20 years patent life -‐ Time2Mkt = Short Exclusivity

Drug Development: it is a long process


Success rates from first-‐in-‐man to registra>on [Data from the ten biggest drug companies 1991–2000]

Less than 1 in 50 early drug discovery projects end with a drug in the market

•  DISCOVERY: cumula>ve aari>on is ~ 80%; ~ 1 in 5 projects gets as far as selec>ng a compound for clinical trials

•  DEVELOPMENT: aari>on between selec>ng a compound and marke>ng is ~ 90%; ~ 1 in 10 projects reach the market

High akriLon rate and risk of failure


Why compounds fail in development?


•  ñRegulatory requirements – (efficacy and safety) •  Targe>ng (profitable) indica>ons: rare disease or chronic •  Restric>on in reimbursement by na>onal healthcare authori>es •  Too much manager and few science (CEOs with no scien>fic background)

•  Pressures for fast returns by shareholders •  Conformism (benchmarking mania on targets and technology) •  Merger mania (during past five years, top ten pharma have eliminated more than 200,000 jobs)

•  The end of Blockbuster era / focus on rare disease (one shot treatment at higher price)

Industry R&D spending is growing vs low producLvity and lack of innovaLon


•  Lack of understanding of complex disease biology

•  Lack of accurate and efficient methods for target idenLficaLon/validaLon

•  Lack of “conLnous validaLon process” of the targets (Basic research and following target’s valida>on ojen not closely connected)

•  Lack of accurate and efficient methods for paLent straLficaLon

This is why science is key!!!

Boklenecks in drug discovery/development:


“…erosion in confidence in the industry and its products … …may be moving closer to a pharmaceutical ‘ice age’ and the potential extinction of the industry, at least as it exists today…”

“…Wall Street and consultants argue that shareholders will be best served by Big Pharma ending all early-stage drug research entirely.. due to limits on their internal capacity to innovate ……to license in new compounds from smaller biotech-style companies, or from academia…“

report from analysts at Morgan Stanley-Financial Times Feb 1,2010

Nature Rev. Drug Discov. 9, 203 (2010)

•  Industry R&D spending is growing vs low producLvity and lack of innovaLon •  The socio-‐economic demand and high failures rate are forcing pharma industry to

reassess R&D strategies to improve efficiency and producLvity •  The pharmaceuLcal industry is currently embracing unprecedented levels of

change

The result? An high need for collaboraLon


•  Reduc>on of public funds for research •  Absence of specific funds dedicated to pre-‐clinical and clinical development (TRANSLATIONAL RESEARCH)

•  GlobalizaLon of the compeLLon for na>onal & interna>onal resources

•  Emergence of new scienLfic paradigm (biotechnologies)vs the conven>onal pharma R&D (chemistry)

Partnership with Pharma: key driver for the Academia and vice versa


•  Licensing revenues •  Start-‐up crea>on

GeneraLng new funding sources


•  Favor translaLonal research (absence of specific funds dedicated to pre-‐clinical and clinical development)

•  Be akracLve for pa>ents by offering innova>ve therapeu>c solu>ons (trial of new drugs)

Compete at the global level


HIV Treatment: EMTRIVA 1990: first patent filed by Emory University, Atlanta 1996: licensed to Triangle pharmaceu>cals 2003: approved by FDA and commercialized by Gilead Sciences

Cancer (glioma): Temodal®,Temozolomide 1980s: developed by Cancer Research UK 1990s: licensed to Schering-‐Plough. 2007: approved by NICE for brain tumors

MulLple Sclerosis: COPAXONE 1971: first Patent filed by Yeda (TTCompany Weizmann Ins>tute Israel). 1987: licensed to Teva PharmaceuLcals Ltd. 1996: approved by FDA

From Academia to Market


NASDAQ Biotechnology Index (^NBI) -‐ NASDAQ -‐ DOW-‐JONES

The Biotech Market


Jazz Pharmaceu>cals buys the Italian rare-‐disease drug developer Gen>um for 1 Billion USD

Intercept shares at Nasdaq has rocketed from 70 to 450 dollars in a single day (10 January)

250 Mln €

Okairos is developing the first Ebola vaccine

Biotech in Italy: a great opportunity

Tra le 15 biotech piu promeaen> (Fierce Biotech) Esempio virtuoso di

tech transfer salen>no (2006)


The “Death Valley”

Industry

Academia

Difficult to build a “safe road” from research to market


Academic Research Centers

Pharma Biotech

Academic Hospitals

Target Iden>fica>on Drug Discovery, Development, Market

Clinical Development

The LIMIT: disease mechanisms’ knowledge is limited at the academic stage

The current model: a segmented process


Provides the Know-‐how on drug development

Pharmas and

Biotechs

Provides the Know-‐how on disease-‐mechanisms

Academic Research Centers Provides the scien>fic

and clinical ra>onale for the drug

Hospitals

The advantage: disease mechanisms’ knowledge pervades the en>re process, interac>on is a key for success

Provides rules for protec>on of pa>ents Local

Governments

The ideal model: integraLon to create value


Which are the challenges?

Ø What is changing? From the sole figure of the business angel inclined to fund early stage

projects, new financial tools are emerging: •  increasing presence of Corporate Venture Capital (i.e. Novar>s, J&J, Roche,

Bayer)

•  Seed investments funds directly owned by universi>es’ technology transfer offices ( Imperial Innova>ons, Karolinska Investment FUND I, Momentum Fund Tel Aviv University …)

•  Open innovaLon models to foster the innova>ve performance of the big

corporates ( GSK DPAC -‐ BAYER -‐ NOVARTIS BioCamp -‐ J&J Innova>on)


•  Achieve a change in the researchers’ culture and approach to science: aiming also to reach pa>ents through applied research

•  Thinking long term (tech transfer return in 5-‐10 year)

•  Working together (management/scien>sts/clinicians each focusing on its task) to reach common objec>ves

•  Addressing complexity earlier: collabora>ons with Universi>es and Professor affilia>ons (i.e. we have agreement Universita di Milano, Is>tuto Italiano di Tecnologia, Universita’ di Pisa, Universita’ di Pavia…)

Which are the challenges?


TTOFFICE

ADMINISTRATION •  low costs •  revenues •  control/burocracy

RESEARCHERS •  services •  patents •  publica>ons

DEAN OF RESEARCH •  services •  freedom of research •  poli>cs

COMPANIES AND VC •  efficiency •  speed •  authority

Why TT offices are (parLally) ineffecLve


A new vision of the Technology Transfer to allow the integraLon

BASIC MODEL: –  Technology Transfer (“Tech Transfer 1.0”) “The IFOM-‐IEO MODEL”: –  Technology Development (“Tech Transfer 2.0”)


TTCOMPANY

SHAREHOLDERS -‐President -‐Board of Directors

MISSION OBJECTIVES GOALS

COMPANIES AND VCs -‐efficiency -‐speed -‐authority

The importance of being a company


Biotech/Pharma

Target Validation

Target ID

Hit identif.

Hit to lead

Lead opt.

Preclin. Dev.

Clinical trials

Academy

Tech Transfer 1.0 The IFOM /IEO model

Academy Biotech/Pharma

PARTNERING AT LATER STAGE, A DE-‐RISKED MOLECULE

TTFACTOR

Our vision of Drug Discovery Process


•  Self funded “industry-skilled” small molecule program;

•  Science driven target identification and validation integrated with drug discovery efforts

•  Targeting cancer’s “hottests targets”

•  Major collaboration with MD Anderson Applied Cancer Institute in epigenetics

IEO Drug Discovery Program (DDP)


•  a technology transfer company owned by IFOM and IEO

•  exclusive licensee of all IEO’s and IFOM’s IP rights

•  with exclusive right to nego>ate and sign contracts with THE FOR PROFIT SECTOR in name and on behalf of IFOM and IEO

•  Exclusive consultants Centro Cardiologico Monzino

One step to decision and execuLon in all makers related to IP exploitaLon

TTFactor’s corporate backbone


Key “TT” FACTORs

•  A Company facing Companies… A light structure allowing a >me effec>ve decision process and an efficient management of the nego>a>on •  An interna>onal Board of Directors To take the advantage of years of succesful experience in technology transfer (improved learning curve) •  Bring science to Market A strategic Business Development Advisory Board to help tailoring the market proposal for each project


Pier Giuseppe Pelicci, President -‐ IEO Claudio Basilico -‐ New York University Leonardo Biondi -‐ IFOM Mario Cesana -‐ IEO Andrea Cuomo -‐ ST Microelectronics Marco Foiani -‐ IFOM Isaac Kohlberg -‐ Harvard University Tomas Lindhal -‐ Cancer Research UK Elisabeaa Petrucci -‐ FIRC Domenico Triarico -‐ IEO

Daniela Bellomo, Managing director Marzia Fumagalli, Intellectual Property Jacopo Franchini, Business Development Giulia Negri, Marke3ng Barbara Gallone, Assistant

Team Board of Directors

Team and Board of Directors

Giulio Draeaa, MDACC Isaac Kohlberg, Harvard University Nagesh Mahantappa, CEO Scholar Rock Kazumi Shiosaki, MPM Capital Katherine Turner, Scholar Rock

Business Advisors


How do we operate?

abandon

more data needed abandon •  Novelty search •  Market search •  Manageability

Feedback from Companies

Business Development Advisory Board

Develop Further (Internally or via Spin off)

License

Patent porsolio

In-‐licensing +

abandon

InvenLons

13


TTFactor Method of antigen loading for immunotherapy

I FOM-IEO-Campus, Mi lan, I ta ly

Last

up

da

te 0

2.2

01

1duction is in preparation for Phase I; the clinical trial in melanoma patients is planned for June-July 2011.

Applicabil ityNew method to generate potent DC-based

tumor vaccines

• Adjuvant treatment (to elimate mini-

mal residual disease) for the moment in

melanoma but it can be extended to other

diseases

• Metastatic melanoma

The European Institute of Oncology (IEO)

is available for clinical support, hosting

several studies on melanoma.

OpportunityWe are looking to partner this program for

further development with companies in

immuno-therapeutics and tumor vaccine.

ReferencesSaccheri F. et al. Bacteria-induced gap

junctions in tumors favor antigen cross-

presentation and antitumor immunity. Sci

Transl Med. 2010 Aug 11; 2(44): 44ra57.

Avogadri, F., et al.. Eur. J. Immunol. 2008

Jul;38(7):1937-47.

Patent ApplicationsUS 61/370,599

TTFactor (Sr l )V ia Adamel lo, 1620139 Mi lan ( I ta ly )

Germano Ferrari PhD, MBABusiness Development Manager

T +39 02 94375.140 E germano.ferrar [email protected] W www.ttfactor.com

IntroductionDendritic cells (DCs) are key players in the

activation of T cells. DCs are endowed

with the ability to present exogenous

antigens that have not been generated

within DCs for the activation of T cells, via

the cross-presentation pathway. Cross-

presentation is required for the initiation

of effective anti-tumor T cell responses

and the repertoire of presented peptides is

crucial to activate T cells that will recognize

and kill tumor cells. However, the antigen

presentation machinery, and in particular

the proteasome, differs between tumor

cells and DCs. A major drawback is that

DCs could process and present peptides

that are different from those presented by

tumor cells, thus initiating a tumor-specifi c

response that will not recognize the tumor.

Brief descriptionWe show that bacteria can be successfully

used to induce tumor to DC communica-

tion via gap-Junctions allowing cross-pre-

sentation of tumor antigens and effective

activation of tumor specifi c immune re-

sponses. Salmonella typhimurium infection

facilitates the cross-presentation of tumor

antigens and its exploitation can generate

potent DC-based tumor vaccines.

Thus, we have developed a new method of antigen cross presentation for immunotherapy, that has proven very effective in mice (see fi gure). Mice vaccinated with DCs loaded with bacteria-treated tumor cells are fully protected against challenge with the highly aggressive B16 melanoma. This mechanism has been confi rmed on hu-man cells in vitro and is under in vivo validation. The protocol for GMP pro-

2. Prior art & Market intelligence 5. Find partner and make the deal

1. IP culture & new inven>ons 3. Filed patent applica>on 4. Promote it and Publish


39

•  Cash-‐in at sign (upfront) •  Cash-‐in when reaching development goals (milestones)

•  Cash-‐in once on the market (royal>es on sales)

MARKET -‐ PATIENTs Research Institution

Company

Right (development, marke3ng, distribu3on)

Upfront +

milestones

Royalties (% on sales)

A way to finance the Research Ins>tu>on and get the commitment from the developer (industrial partner)

•  Cash-‐in at sign (upfront) •  Cash-‐in when reaching development goals (milestones)

•  Cash-‐in once on the market (royal>es on sales)

What does a licensing agreement mean?


PROJECT SOURCE IP DISCOVERY PRECLINIC CLINIC

PARTNERED

uPAR ANTAGONISTs & BIOMARKERs IFOM ✔

LDH INHIBITORS IEO ✔

mPTP INHIBITORS IEO/GNX ✔

HDAC INHIBITOR IEO/GNX ✔

miRNA DIAGNOSTIC TEST IFOM/IEO ✔

STEM CELL SIGNATURE IFOM/IEO

LSD-‐1 INHIBITORS IEO ✔

AVAILABLE FOR PARTNERING IN ONCOLOGY

RADIO-‐PHARMACEUTICALS ST/IEO ✔

NON CODING RNA (DDRNA) IFOM ✔

TARGET ID&VALIDATION IEO

scFv ANTIBODIES TARGETING TUMORs IEO

AVAILABLE FOR PARTNERING IN OTHER INDICATIONS

SHORT TSLP PEPTIDE IEO ✔

BACTERIAL/PROBIOTIC PLATFORM IEO ✔

BETA-‐CATENIN INHIBITORS IFOM ✔

GPR17 MODULATORS CCM ✔

iPS GENERATION FACTOR IFOM ✔

SMARTFOOD IEO

PATIENT DISEASE MODEL / DRUG SCREENING IEO

STROKE (HEARTH/BRAIN)

PARTNERED ONCOLOGY

PARTNERED CANCER Epigene>cS

IMMUNOTHERAPY

ONCOLOGY/AGEING

PARTNERED ONCOLOGY

PARTNERED DERMATOLOGY HEART DISEASE

PARTNERED LUNG CANCER

INFLAMMATION (IBD)

BRAIN RARE NGIOMA

✖

BREAST CANCER

IART-‐BREAST CANCER

NEGOTIATION

NUTRITION & SCIENCE

Biotech & VC

Biotech & VC PARTNERED

PARTNERED

AGGRESSIVE TUMORs

AGGRESSIVE TUMORs

REGEN. MEDICINE

AUTISM & WILLIAMS

A growing pipeline


•  104 invenLon disclosures from scien>sts 16 new patent families and 2 trademarks -‐ 7 in-‐licensed patent families

•  190 contracts with biotech/pharma/food companies, and selected Academic InsLtuLons

•  80 Non Disclosure Agreements including GSK, J&J Roche, Novar>s etc

•  9 license and/or co-‐development with European investment firms and companies

•  a major alliance on drug discovery for epigene>c targets with MDACC

Food

Academia

Pharma & BIOTECH

In FOUR years

A solid track record


In TTFactor we aim not only to collect the but also to culLvate the tree. There are several models of Tech Transfer, more or less ac>ve towards the market depending on the features and voca>on of the model chosen. IFOM and IEO have invested in a innova>ve model of technology transfer in the Italian landscape:

A simple organiza>on, comparable on one hand to the industrial world and able, on the other one, to adapt itself to IEO and IFOM

strategies in R&D

Conclusion


4. Career Development Session


VIDEO INTERVISTA SUL WORKSHOP TTFACTOR

Speakers:!•  Gianmario Verona,

Vice Rector of Faculty, SDA Bocconi outgoing Director MBA!

•  Federica Draghi, Business Development Director, Genextra!

•  Rocco Paracchini, Senior Manager Global Sales, Aptalis Pharma!

•  Olga Capasso, Patent Attorney, De Simone & Partners!

•  Marzia Fumagalli, Intellectual Property Manager, TTFactor!

•  Antonino Amato, Director Clinical Trial Center, Policlinico Gemelli!

•  Marco Morello, Manager Healthcare & Life Science Division, PageGroup!

!!!Moderator:!•  Daniela Bellomo,! Founder and Managing Director, TTFactor!

Agenda:!14.00 "Registration""14.30 "Round Table 1!"

"Careers in finance, investment, !corporate business development !"G.Verona, F.Draghi, R.Paracchini!

!!Recent experiences from your peers""E.Beltrami, J.Sgualdino, N.Bacchi!

!15.40 "Q&A""15.50 "Coffee Break!!16.15 !Round Table 2!

!!!Careers in intellectual property, !!tech transfer, regulatory & drug safety!!O.Capasso, M.Fumagalli, A.Amato!!!!A look at the Italian !healthcare job market and hints !on how to make a CV appealing !!M.Morello!

!17.20 !Q&A and meeting end"

Looking beyond the lab Workshop on career opportunities for qualified scientists

21 October 2014 Campus IFOM-IEO, Conference Room, Bldg. 9

IN COLLABORATION WITH: ORGANIZED BY:

Follow TTFactor on: #lookingbeyondthelab


Jacopo Franchini, MSc Business development & marketing Manager

•  Prior joining TTFactor, Jacopo was Sales Area Manager for INDIA and MENA regions at Solmag-‐Olon, an API manufacturer.

•  Previously he served as Contract Coordinator in the Business Development unit of MolMed S.p.A (MLM.MI), a Biotech Company focused on oncology.

•  Internship at King’s College Business London Ltd, the tech transfer company of a major university in UK.

•  Jacopo holds a Master degree in Pharmaceu>cal Biotechnology from Vita Salute San Raffaele University and he aaended different post graduate courses on patent management and business development: –  MIP Corporate Master Program in Accoun>ng and Financial statements; –  Intellectual Property and patents post graduate course at Universita’ di Pavia; –  Business development course and licensing at Assobiotec Milano


Marzia Fumagalli, PhD, LLM Intellectual Property Manager

•  Marzia Fumagalli joined TTFactor in 2011, after having collaborated with the Company since 2010.

•  She holds an LLM (Master of Laws) in IP Law and Management (MIPLM) from CEIPI, Center for International Intellectual Property Studies, of University of Strasbourg.

•  Prior joining to TTFactor, she was a postdoctoral research fellow in biomedical oncology at IFOM (The FIRC Institute of Molecular Oncology Foundation).

•  Marzia obtained her PhD in Molecular Medicine from SEMM, the European School of Molecular Medicine, and she holds a Master Degree in Medical Biotechnology from University of Milan


CV • Founder and current Managing Director of TTFactor Srl (Milan) since 2010 • Director Technology Transfer Office at San Raffaele Hospital (Milan) 2002-‐2010 • Mater Business AadministraLon at University of Queensland Business School • Senior Officer at IMBcom (TTO -‐ University of Queensland) 2001-‐2002 • Post Doc at Queensland InsLtute for Medical Research (Australia) 1996-‐2000 • PhD student at St Georges’ Hospital Medical School (London, UK) 1992-‐1996 Other:. Member of the Board of Directors of the Parco Tecnologico Padano (www.technoparco.org), Italy’s largest scien>fic park dedicated to the agri-‐food sector by nominaLon by the Mayor of Milan

Daniela Bellomo, PhD, MBA Direttore Generale TTFactor


Daniela Bellomo, Managing director Marzia Fumagalli, Intellectual Property Jacopo Franchini, Business Development Giulia Negri, Marketing Barbara Gallone, Assistant

What I like the most of my job and which are the challenges…

Every day I learn something new both from science and from business

You need both an eye for details and an open mind

for the big picture

I enjoy working in a nimble ad streamlined

team with clear objectives

It is hard to estimate the value of an early technology still far

away from the market

It gives me a cross view of science

We have to keep everyone’s

expectations realistic

I love exploring the unknown and being part of

discoveries that will contribute to new

therapies

You work under pressure, managing many different tasks whilst respec3ng

deadlines


If you wish to learn more.. Tech Transfer: AUTM (hap://www.autm.net/) Associa>on of University Technology Managers ProTon (hap://www.protoneurope.org/) European Associa>on for Knowledge Transfer Netval (hap://www.netval.it/) Network for the valorisa>on of the University Italian research

Intellectual Property and Patents: EPO (hap://www.epo.org/) European Patent Office WIPO (hap://www.wipo.int/about-‐ip/en/iprm/) World Intellectual Property Organiza>on CEIPI (hap://www.ceipi.edu/) at Univ of Strasbourg Centre d'Etudes Interna>onales de la Propriete Intellectuelle

www.vactor.com

Follow us on @TTFactor

Presentations & Public Speaking

Ldb 145 geni mutanti_2014-11-07 franchini - marketing e trasferimento tecnologico